Table 4.

Cox regression of incident ILD while on first HER2-directed therapy, n = 479

Variable	P value	HR (95% CI)	N	N events
Age > 65 years	0.716	1.1 (0.7, 1.8)	123	24
Black/African-American	0.12	1.5 (0.9, 2.6)	93	20
BMI: Overweight (25–30)	0.221	0.7 (0.4, 1.3)	126	17
BMI: Obese (30+)	0.797	0.9 (0.6, 1.6)	167	31
Ever smoker	0.543	1.2 (0.7, 1.8)	204	38
Prior lung comorbidities	0.099	1.9 (0.9, 3.8)	276	67
Prior thoracic radiation	0.168	1.7 (0.8, 3.5)	38	9
Prior ILD-inducing systemic therapy	0.544	0.9 (0.5, 1.4)	156	24
< 1 month from mBC to index	0.143	1.4 (0.9, 2.2)	222	40
ECOG: > 0	0.063	1.9 (1, 3.6)	121	26
Has prevalent ILD at index	< 0.001	13 (7.4, 22.7)	81	48

BMI body mass index, CI confidence interval, ECOG Eastern Collaborative Oncology Group, HR hazard ratio, ILD interstitial lung disease, mBC metastatic breast cancer, N number